NVR Inc. Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? NVR Inc. Common Stock trades at $5,798 (market cap $15.28B), while uniQure N.V. Ordinary Shares trades at $20.71 (market cap $1.45B). The key difference: NVR Inc. Common Stock is far larger — about 10.5× uniQure N.V. Ordinary Shares's market cap, and NVR Inc. Common Stock is more actively traded (53,948 versus 3,323,243). Which is the better fit depends on your goals — on Pluang, investors hold NVR Inc. Common Stock for 0 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| NVR | QURE | |
|---|---|---|
Market Cap | $15.28B | $1.45B |
Volume | 53,948 | 3,323,243 |
Sector | Consumer Cyclical | Health |
52-Week High | $8.10K | $70.59 |
52-Week Low | $5.56K | $9.03 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $15.18B | $707.46M |
Signals from Pluang's Aura AI — not financial advice
NVR trades at $5,797.61, up 0.83% today, with a P/E of 15.07 and P/S of 1.79. Recent earnings missed estimates in Q1 and Q2 2026, with revenue and net income projected to decline in 2026. The stock faces headwinds from margin pressure and softer homebuyer demand, as highlighted by Zacks naming it Bear of the Day on October 9, 2026. Despite this, strong profitability metrics like a 31.54% ROE and consistent cash flow from operations support its financial resilience.
The outlook is cautious due to earnings misses and a projected revenue drop, but the asset-light model and share buybacks provide stability. Risks include mortgage rate sensitivity and competitive pressures, while analyst consensus leans neutral with a $6,550 price target. Patient investors may find value if housing demand recovers.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
NVR Inc. is a homebuilder operating through homebuilding and mortgage banking segments, building single-family homes, townhomes, and condominiums under the Ryan Homes, NVHomes, and Heartland Homes brands. It uses a land-light model, acquiring lots through third-party option agreements rather than holding large land inventories, and provides mortgage and title services through NVR Mortgage.
Read more on NVR →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →